Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus News

Thu, May 8, 2025, 12:29 AM 4 min read

• Total Revenue: $111.6 million, a 61% maturation implicit the archetypal 4th past year.

• Full Year Revenue Guidance: Updated to $435 cardinal to $450 million.

• LIVMARLI Global Net Product Sales: $73.2 million, implicit 70% summation compared to Q1 2024.

• US LIVMARLI Sales: $49.5 million.

• International LIVMARLI Sales: $23.7 million.

• Bile Acid Products Net Product Sales: $38.4 million, 47% maturation implicit the aforesaid 4th past year.

• Cash, Cash Equivalents, and Investments: $298.6 cardinal arsenic of March 31.

• Total Operating Expense: $126.8 million.

• R&D Expense: $46 million.

• SG&A Expense: $57.7 million.

• Cost of Sales: $23 million.

• Noncash Stock-Based Compensation Expense: $15.8 million.

• Cash Flow: Operating currency travel affirmative for the quarter.

• Cash Contribution Margin: Improved from astir 47% to 53% year-over-year.

• Warning! GuruFocus has detected 4 Warning Signs with MQ.

Release Date: May 07, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• Mirum Pharmaceuticals Inc (NASDAQ:MIRM) reported a record-breaking 4th with full revenues reaching $111.6 million, marking a 61% maturation implicit the archetypal 4th of the erstwhile year.

• The institution has updated its full-year gross guidance to $435 cardinal to $450 million, driven by robust maturation from each 3 of its commercialized medicines.

• Mirum Pharmaceuticals Inc (NASDAQ:MIRM) received 3 important regulatory approvals since the commencement of the year, including FDA support for CTEXLI and LIVMARLI successful Japan, enhancing its maturation drivers.

• The company's pipeline is progressing well, with the VISTAS survey of volixibat successful PSC nearing enrollment completion and promising interim information from the VANTAGE survey successful PBC.

• Mirum Pharmaceuticals Inc (NASDAQ:MIRM) is operating currency travel affirmative for the 4th and expects to support this presumption for the afloat year, indicating beardown fiscal health.

• Total operating expenses for the 4th were $126.8 million, which includes important R&D and SG&A expenses, impacting wide profitability.

• Despite beardown gross growth, Mirum Pharmaceuticals Inc (NASDAQ:MIRM) is not yet profitable successful presumption of GAAP owed to non-cash charges.

• The institution faces challenges successful diligent recognition for CTEXLI, arsenic it is an underdiagnosed condition, requiring accrued efforts successful illness awareness.

• Inventory dynamics successful planetary markets person introduced variability successful income figures, which could impact aboriginal gross consistency.

• The competitory scenery for volixibat successful PSC remains uncertain, with nary FDA-approved therapies presently available, posing a situation for marketplace positioning.